Answers are grounded in this paper and cite their sources.
This study examines formulary coverage of brand-name adalimumab and biosimilars across Medicare Part D plans.
No takes yet. Share an insight, caveat, or question.
Klebanoff et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: